---
title: Early versus late response to PD-1-based immunotherapy in metastatic melanoma
date: '2024-08-30'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39213786/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240831181359&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: Less than 10 % of metastatic melanoma patients achieved
  an early response during the first 3 months of PD-1-based immunotherapy. Early responders
  were not superior to late responders in terms of response durability and ...'
disable_comments: true
---
CONCLUSION: Less than 10 % of metastatic melanoma patients achieved an early response during the first 3 months of PD-1-based immunotherapy. Early responders were not superior to late responders in terms of response durability and ...